版本:
中国

BRIEF-Astrazeneca presents new data underpinning safety profile and real-world cv outcomes of Farxiga at ADA 2017

June 12 Astrazeneca Plc

* Astrazeneca presents new data underpinning safety profile and real-world cv outcomes of farxiga at ada 2017

* Astrazeneca Plc -comprehensive updated analysis provides evidence on safety profile of farxiga, including no imbalance in lower-limb amputations

* Says new analyses from cvd-real examine reductions in cv events for sglt-2 inhibitors

* Astrazeneca - in an updated safety analysis, data pooled from 30 phase iib/iii clinical trials for dapagliflozin showed no new safety signals

* Astrazeneca - data from 30 phase iib/iii clinical trials for dapagliflozin showed incidence of adverse events generally similar to that in control groups Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐